Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures

Leukemia Research

Volumn 33, Issue 7, 2009, Pages 997-1000

  Podhorecka, Monika ^a   Halicka, H Dorota ^b   Klimek, Piotr ^a   Kowal, Malgorzata ^a   Dmoszynska, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; CLL; DNA damage; Fludarabine; Thalidomide

Indexed keywords

CASPASE 3; FLUDARABINE; HISTONE H2AX; SERINE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG POTENTIATION; ENZYME RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL CULTURE TECHNIQUES; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HISTONES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; PHOSPHORYLATION; THALIDOMIDE; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 67349104452     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.023     Document Type: Article

References (8)

1. Chanan-Khan A.A., Miller K.C., Takeshita K., Koryzyna A., Donohue K., Bernstein Z.P., et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106 (2005) 3348-3352
2. Tanaka T., Huang X., Halicka H.D., Zhao H., Traganos F., Albino A.P., et al. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71 (2007) 648-661
3. Tanaka T., Halicka H.D., Huang X., Traganos F., and Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 17 (2006) 1940-1945
4. Collins R.J., Verschuer L.A., Harmon B.Y., Prentice R.L., Pope J.H., and Kerr J.F. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro. Br J Haematol 71 (1989) 343-350
5. Molica S. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 48 (2007) 866-869
6. Laurenti L., Piccioni P., Tarnani M., De Padua L., Garzia M., Efremov D.G., et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res 31 (2007) 253-256
7. Parman T., Wiley M.J., and Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5 (1999) 582-585
8. Liu L., and Wells P.G. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic Biol Med 19 (1995) 639-648